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This work aimed to verify propionic acid toxic effects, and to investigate the possible neuroprotective 
effects of creatine against it. Propionic acid (PA) toxicity together with the effect of creatine (CR) was 
studied on neuroblastoma SH-SY5Y brain cells in culture. In the first group, cells were divided and 
treated with different concentrations of PA, while the second group was pre-treated with creatine to test 
its neuroprotective effect in PA-intoxicated cells. Comet assay and DNA fragmentation studies were 
used to examine genotoxicity and apoptosis of cells. The results emphasized the neurotoxicity of 
propionate to neuroblastoma cell line SH-SY5Y by DNA fragmentation that increased in a dose- and 
time-dependent manner. More importantly, our data confirms a possible neuroprotective effect of 
creatine against the neurotoxic effect of propionic acid. The obtained in vitro data supports and explains 
the in vivo neurotoxic effect of PA and proves its DNA damaging effect which could clarify its role in the 
etiology of autism, a phenomenon recently raised by many researchers. It also supported the 
accumulating literature which describes creatine as a potential bioactive agent against neurotoxicity. 
With sufficient research and clinical trials in future, this could prove to be successful in treatment or 
management of autism as a neurodevelopmental disorder recently related to PA neurotoxicity. 
 






Propionic acid (PA) is a short chain fatty acid that is 
dietary obtained (Zarate et al., 2004), or naturally pro-
duced in cellular metabolism (Thompson et al., 1990). PA 
is thought to be involved in behavioral and neuropatho-
logical abnormalities reported in some neurological condi-
tions (Wajner et al., 2004). The chemical properties of 
this weak acid facilitate its easy access to the brain; 
where it can accumulate, leading to intracellular acidifica-
tion (Bonnet et al., 2000). These facts sugges that central 
nervous system (CNS) is sensitive to high PA levels 
(Brusque et al., 1999). 
Propionic acidemia is well-recognized as a genetic neu- 
rodevelopmental metabolic disorder, characterized by 
elevated PA accompanied by developmental delay and 
various neurological and behavioral manifestations (Feliz 
et al., 2003). PA neurotoxicity develops from consequent 
alterations at many levels, like metabolism (Brass and 
Beyerinck 1988), inflammatory response (Cavaglieri et al., 
2003), and neurotransmission (Cannizzaro et al., 2003).  
There has been a growing interest on possible environ-
mental agents involved in the aetiology of autism as a 
neurodevelopmental disorder of increasing prevalence, 
such as chemical toxins, which could act during critical 
periods of pre- and early postnatal development (Lawler
 








et al., 2004). Of particular relevance to this argument, 
propionic acid (PA) has often been reported to induce a 
number of behavioral changes and neuroinflammatory 
responses in rats reminiscent of autism spectrum 
disorder (ASD) (El-Ansary et al., 2012). This dietary short 
chain fatty acid is a common food preservative and 
metabolic endproduct of enteric bacteria in the gut. 
Although mostly accumulating in the gut, PA can readily 
cross the gut-blood and blood-brain barriers (BBB) and 
gain access to the CNS. In the brain, it can cross cell 
membranes and accumulate within cells, inducing intra-
cellular acidification (Bonnet et al., 2000, Karuri et al., 
1993), which may alter neurotransmitter releases and, 
ultimately, neuronal communication and behavior 
(Cannizzaro et al., 2003, Severson et al., 2003). MacFabe 
et al. (2007) showed that intraventricular infusion of PA 
can change both brain and behavior in the laboratory rat 
in a manner that is consistent with symptoms of human 
ASD. The behavioral, neuropathological and biochemical 
findings in the MacFabe's PA model provide further 
support the hypothesis that autism may be a systemic 
metabolic encephalopathic process affecting the brain. 
They have also found evidence of reversible impairments 
in social behavior following PA exposure (Shultz et al., 
2008). This was ascertained through the recent work of 
El-Ansary et al. (2011b) in which they proved the efficacy 
of omega-3 fatty acids to protect against PA-induced 
neurotoxicity in rat pups.  
The derivative, 3-nitropropionic acid (3-NP), has also 
been associated with neuronal degeneration, cytotoxicity, 
and various brain lesions (He et al., 1995; Ryu et al., 
2003). PA and 3-NP are receiving lots of interest in deve-
lopment of in vitro and animal models for better under-
standing of neurological conditions like Huntington's 
disease (HD) (Borlongan et al., 1997) and autism (MacFabe 
et al., 2007). Discoveries of promising neuroprotective 
agents have urged the need for such studies to investi-
gate the possibilities (Alexi et al., 2000).   
Among the promising neuroprotectors is creatine (CR) 
(N-aminoiminomethyl-N-methylglycine), a natural guani-
dino compound that can be dietary obtained or endo-
genously synthesized. The brain can synthesize its own 
CR or take it up from circulation by specific creatine 
transporters (CRTs) (Braissant et al., 2001). In neural 
cells, CR is charged-up to phosphocreatine (PCr) by 
creatine kinase (CK), and excess is degraded to create-
nine (Wyss and Kaddurah-Daouk, 2000).  
The critical role of CR and PCr in maintaining energy 
requirements as components of the CK system is well 
established. However, CR is thought to have additional 
important functions and neuroprotective roles in the CNS 
(review Andres et al., 2008). Recent in vitro findings 
suggested that CR helps to protect neurons against 
hyperammonemia and hyper-osmotic shock (Bachmann 
et al., 2004; Alfieri et al., 2006). A direct anti-apoptotic 
effect for CR and functions as direct antioxidant have been 





is a strong evidence for CR role as a neuromodulator 
(Almeida et al., 2006), and its administration exerted 
positive effects on mental performance (Rae et al., 2003). 
PCr can stimulate synaptic glutamate uptake to prevent 
excitotoxicity (Xu et al., 1996). All these protective effects 
have urged researchers to investigate CR as a possible 
neuroprotector against various toxins (including 3-NP) 
used in neuropathological in vitro and in vivo models 
(Brewer and Wallimann 2000; Shear et al., 2000; Berger 
et al., 2004; Vis et al., 2004; Andres et al., 2005; Heitz et 
al., 2008).  
CR administration has proven to be protective of 
neural, cardiac and muscular tissue in a variety of patho-
genic conditions. A creatine-supplemented diet signi-
fcantly improved neuronal survival in rats administered 
malonate or 3-NP to deplete succinate dehydrogenase 
and mimic the pathophysiology of HD (Matthews et al., 
1998). In Parkinsonian mice produced by N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure, oral 
supplementation with creatine or cyclocreatine showed 
marked improvement of dopamine levels and survival of 
substantia nigra neurons (Matthews et al., 1999). 
This work aimed to verify the in vitro DNA damaging 
effects of PA on neuroblastoma cells, and to investigate 
possible antagonism of CR as a promising neuropro-
tective effecter.  
 
 




Human neuroblastoma cell line SH-SY5Y, purchased from Ameri-
can Type Tissue Culture (ATTC; Manassas, VA), were cultured in 
Dulbecco’s Modified Eagles Medium (DMEM), supplemented with 
15% fetal bovine serum (FBS), 2 mM L-glutamine, 1000 mg/ml 
(high glucose) D-glucose, 1% non-essential amino acids, 100 U/ml 
Penicillin, and 100 μg/ml Streptomycin, in a 95% air and 5% CO2-
humidified incubator at 37°C. They were grown in T-25 flasks until 
70 to 80% confluence, and then split for sub-culturing (Encinas et 






To study propionic acid (PA) toxicity and the effect of creatine on it, 
the brain cells were divided into two groups. In the first group, cells 
were divided and treated with different concentrations of PA, which 
was added to the culture media to reach the final concentrations (0, 
5 and 10 mM). This group was used for studying the effects of PA 
toxicity (Ryu et al., 2003).  
The second group of cells was used to study the possible neuro-
protective effects of creatine (CR) against PA toxicity. Those cells 
were divided and pretreated with different concentrations of CR, 
which was dissolved in the media to reach final concentrations (0, 
12 and 24 mM) (Vis et al., 2004). CR-pretreated cells were sub-
divided and followed by PA treatments (0, 5 and 10 mM). Cells with 
zero PA and zero CR served as the control group for the entire 
study. Cells with zero PA were used to show the effects of CR treat-
ment on healthy cells without the PA toxicity. Finally, cells with zero 
CR were used to study the toxic effects of PA on brain cells. To 





with both CR and PA; for each of group of cells, two different con-
centrations of CR were used (12 and 24 mM). Studying CR effect 
against PA, also allowed us to monitor the effect of dose increase 
for each of CR and PA. The effects of treatments were examined 




Single cell gel electrophoresis (comet assay) 
 
From each group of cells, slides were prepared for a standard 
comet assay as described originally by Singh et al. (1988). About 4 
X 10
6
 cells were mixed with 80 µl of 0.7% low-melting agarose in 
phosphate-buffered saline (PBS) at 37°C in a microtube, and then 
spread over a window microscopic slide. The slides were precoated 
with 150 µl of 0.5% normal-melting agarose in PBS, and were spe-
cially designed for this assay. Then, slides were placed immediately 
in cold lysis buffer, 2.5 M sodium chloride NaCl, 100 mM ethylene-
diamine-tetraacetic acid sodium salt Na2EDTA, 10 mM Tris (pH 10), 
and 1% Triton X-100, at 4°C for a minimal of 1 h. After lysis, the 
slides were drained and placed in a horizontal gel electrophoresis 
tank surrounded by ice, and filled with fresh cold electrophoresis 
buffer (300 mM sodium hydroxide NaOH, 1 mM NaEDTA, pH 13). 
To allow DNA unwinding, the slides were kept in the high pH buffer 
for 20 min. After that, electrophoresis was carried out for 20 min at 
25 V and 300 mA. The slides were then drained and flooded slowly 
with three changes of neutralization buffer (0.4 M Tris, pH 7.5) for 5 
min each, and then stained with 30 ml of ethidium bromide (20 
mg/l), and covered with cover slips. All those steps were performed 
under dimmed light in order to prevent additional DNA damage 
caused by visible light. A total of 50 randomly selected cells per 
slide were analyzed. Imaging was done using a fluorescence micro-
scope (Zeiss Axiovert L410 Inc., Jena Germany), attached to a 
digital camera (Olympus Inc., Tokyo, Japan), and equipped with 
549 nm excitation filter, 590 nm barrier filter, and a 100-W mercury 
lamp. The percentage of DNA in the comet tail "DNA damage" was 





The method described by Chaudhary et al. (2001) was used for 
DNA extraction and agarose gel electrophoresis. After 24 and 48 h 
of treatment, both attached and floating cells were collected, 
washed with PBS, and centrifuged at 1500 rpm for 5 min to preci-
pitate the cells. The cell pellet was resuspended in 0.5 ml of lysis 
buffer, transferred to a microfuge tube and incubated for 1 h at 
37°C. Then, 4 μl of proteinase K was added to the tubes, and they 
were incubated at 50°C for 3 h. To separate the DNA, phenol-
chloroform extraction was carried out by adding 0.5 ml of phenol: 
chloroform: isoamyl alcohol (25:24:1) to each tube with mixing and 
centrifugation at 13,000 rpm for 1 min. The extraction was repeated 
twice, followed by chloroform extraction alone. The resulting DNA 
containing upper aqueous phase was separated, and to that, two 
volumes of ice-cold absolute ethanol and 1/10th volume of 3 M 
sodium acetate were added, followed by incubation on ice for 30 
min to precipitate the DNA. Centrifugation at 13,000 rpm for 10 min 
at 4°C precipitated DNA pellets, which, after discarding the super-
natant, was washed with 1 ml of 70% ethanol. The centrifugation 
step was repeated to remove the last traces of the supernatant 
fraction. The pellet was allowed to dry at room temperature for 
approximately 30 min, and resuspended in 50 μl of Tris-EDTA 
buffer. DNA quantification was conducted using ultraviolet   (UV)    
spectroscopy, and 10 μg of DNA was electrophoresed in a 1.2% 
agarose gel, containing ethidium bromide, in a mini gel tank 
containing Tris-boric acid-EDTA buffer for 2 h under 90 V, using a 
ready-to-use 100 bp DNA ladder (GenScript, USA). Finally, the gel 
was visualized under UV transilluminator (Chaudhary et al., 2001). 






The Statistical Package for Social Sciences (SPSS) computer pro-
gram was used. Results are expressed as mean ± S.D. and all 
statistical comparisons were made by means of independent t-Test 
and P ≤ 0.05 was considered significant.    
 
 
RESULTS AND DISCUSSION  
 
In this work, apoptosis detection techniques, that is, 
single cell gel electrophoresis (comet assay) and typical 
DNA fragmentation assay, were used to verify the 
neurotoxic effects of PA on neuroblastoma cell lines, and 
the antagonistic effects of creatine treatments. The 
results are presented in Figures 1, 2, 3, 4, 5, and 6. 
Our results show increased DNA fragmentation in the 
PA-treated cells compared to control, which was clearly 
evident in the comet assay data and was supported by 
the DNA fragmentation ladder results. After 24 h of 
treatment with 5 mM PA, the comet results (Figure 1) 
showed an increase in the DNA tail length for PA-treated 
cells (2.442 μm) compared to the control (0.541 μm), 
indicating the neurotoxic effect of PA as it caused 
increased nuclear DNA damage and fragmentation. This 
effect worked in a dose-dependent manner, whereby 
more increase in the tail length (to 7.794 μm) was 
observed following 24 h treatment with a higher dose of 
PA (10 mM). Another factor that played a role in this 
matter is the incubation time following the treatments. 
Compared to the results after 24 h, it was noticed that 
with the prolonging of incubation time to 48 h, the PA 
neurotoxic effects manifested stronger. After 48 h (Figure 
2), the tail length for cells treated with 5mM PA increased 
more (3.525 μm), compared to the 24 h results (2.442 
μm) and control (0.781 μm), with the same observation in 
those treated with the higher PA dose (to 13.013 μm). 
The results of the study also confirms an antagonistic 
neuroprotective effect for creatine, demonstrated by 
decrease in the tail length (μm) in the creatine-pretreated 
cells compared to PA-treated cells that were not exposed 
to creatine (Figure 3). The decreases in fragmented DNA 
% further support the results (Figure 4).  
In cells that were pretreated with 12 mM creatine, after 
24 h incubation, the tail length decreased in the group 
treated with 5 mM PA (from 2.442 to 2.095 μm), as well 
as the one treated with 10 mM PA (from 7.794 μm to 
6.230 μm). This effect was dose-dependent, where a 
higher creatine dose (24 mM) caused further decrease in 
the tail length for both 5 mM PA group (to 1.955 μm) and 
10 mM PA group (to 4.971 μm). Like the neurotoxic effect 
of PA, the neuroprotective effect of creatine also 
depended on the time of incubation following treatments. 
After 48 h, the effect of 12 mM creatine pretreatment on 
decreasing PA-induced DNA fragmentation was enhan-
ced in both 5 mM PA (to 2.943 μm) and 10 mM PA 
groups (to 10.401 μm). Similarly, the effect of 24 mM 
creatine pretreatment was increased after 48 h, decree-
sing DNA tail length further in the 5 mM PA group






Figure 1. Single cell gel electrophoresis (comet assay) images for neuroblastoma after 24 h 
exposure. SH-SY5Y cells were exposed to different concentrations of propionic acid (PA) (5 and 
10 mM), in the presence and absence of creatine (CR) at different doses (12 and 24 mM) for 24 
h. Images were taken using fluorescent microscope (Zeiss Axiovert L410, Germany) after 




(to 2.745 μm), as well as the 10 mM PA one (to 8.300 
μm). Cells which were treated with a high dose of creatine 
(24 mM) even showed less fragmentation than the control 
group, which emphasized its possible important neuro-
protection role. The result of DNA ladder test emphasizes 
the results of the comet assay as PA caused DNA frag-
mentations in a dose and time dependent manner. The 
higher fragmentation within 24 h (Figure 5A) was caused 
by 10 mM PA (5 lines of fragmentation; bands) and the 
lowest percentage of compact DNA (14.4 to 54.49%) was  
 
10 mM PA + 24 mM CR 10 mM PA + 12 mM CR 10 mM PA 
24 mM CR Control 12 mM CR 
5 mM  PA 5 mM PA + 12 mM CR         5 mM PA + 24 mM CR 






Figure 2. Single cell gel electrophoresis (comet assay) images for 
neuroblastoma after 48 h exposure. SH-SY5Y cells were exposed to different 
concentrations of propionic acid (PA) (5 and 10 mM), in presence and absence 
of creatine (CR) at different doses (12 and 24 mM) for 48 h. Images were 
taken using fluorescent microscope (Zeiss Axiovert L410, Germany) after 




found in cells treated with 10 mM PA. Within 48 h of 
exposure (Figure 5B), the higher fragmentation (8 lines of 
fragmentation; bands) and the lowest percentage of com-
pact DNA (6.36 to 50.95%) were caused by 10 mM of PA 
as well.  
In addition, the DNA ladder data supported the comet 
assay, confirming the positive effect of creatine in decrea-
sing PA-induced DNA damage, which was evident either 
by decreasing the degree of fragmentation (number of 
bands, Figure 6), or by improving the percentage of com- 
pact DNA (Figure 7) in creatine pretreated cells. 
Apoptosis is now recognized as a normal part of early 
brain development, as well as its possible role in aging, 
and its involvement in neuronal degeneration and the 
progress of neurodegenerative diseases. There are many 
stimuli that are capable of activating apoptosis in neu-
rons, including: glutamate excitotoxicity, excessive cal-
cium flux, mitochondrial dysfunction, and oxidative stress 
(Sastry and Rao, 2000). The mitochondrial toxin 3- NP 











Figure 3. Histogram showing the tail length calculated in µm for the neuroblastoma cells SH-SY5Y treated without and with different 
concentrations of propionic acid (PA) (5 and10 mM), in presence and absence of creatine (CR)  at different doses (12 and 24 mM) for 24 




animal models for some neurological diseases such as 
HD. Through mitochondrial strain and increased oxidative 
stress, they could cause a host of downstream neurotoxic 
processes that leads to apoptotic and necrotic death after 
lesioning (Alexi et al., 2000). In accordance with this 
previous literature, our results confirm the neurotoxicity of 
PA that caused apoptotic DNA fragmentation in neuro-
blastoma cell line. 
Creatine has been suggested to have a multifactorial 
neuroprotective effect, including several aspects, such 
as: anti-apoptosis, antioxidant, metabolic and energy 
regulation, neurotransmitters, and others. This has lead 
to suggest its possible beneficial role in some neurologic 
disorders, which was based on its protection against 
toxins in some in vitro and animal models (Andres et al., 
2008, El-Ansary et al., 2011a).  
Our results support the possible neuroprotection by CR 
against PA, as indicated by the decrease in DNA frag-
mentation after CR treatment, which is supported by 
several previous studies. Increased neuronal survival and 
several neuroprotective effects for creatine administration 
have been observed in many in vitro experiments, in vivo 
models, and some clinical trials for some neurological 
diseases, such as: Huntington's (HD), Parkinson's (PD), 
and Alzheimer's diseases (AD), amyotrophic lateral scle-
rosis (ALS), hypoxic-ischemia, and stroke (Brewer and 
Wallimann 2000; Berger et al., 2004; Dupuis et al., 2004; 
Andres et al., 2005; Tabrizi 2005; Prass  et al., 2007; 
Heitz et al., 2008). Among the models in some of these 
studies, along with other studies, creatine helped to atte-
nuate 3-NP toxicity in neurons, astrocytes, or animal 
brain (Deshpande et al., 1997; Shear et al., 2000; Vis et 
al., 2004). 
Andres et al. (2008) reviewed several studies regarding 
creatine and neurological diseases. As going through the 
available literature, CR seems promising as a neuropro-
tective agent for several neurological diseases which 
could greatly support the result of the present study. Bio-
chemical analyses of brain homogenates from PA-treated 
rats showed mitochondrial dysfunction, impaired energy 
metabolism and brain excitotoxicity (decrease of γ-amino-
butyric acid (GABA) and increase glutamate as an inhibi-
tory and excitatory neurotransmitters, respectively) as the  
main features of PA neurotoxicity (El-Ansary et al., 2012). 
This could help to suggest that the neuroprotective 
effects of creatine recorded in the present study could be 
explained on two integrated mechanisms. Firstly, creatine 
is effective in increasing cellular energy reserves which is 
critically needed to restore normal metabolite transport 
after being impaired by glutamate receptor-dependent 
excitotoxicity. 
Secondly, due to the ability of creatine to slightly inhibit 
the mitochondrial permeability transition pore (MPTP), an 
early event in mitochondrial dysfunction is known to con-
tribute to the apoptotic type of cell death observed with 3-
NP (Behrens et al., 1995, Pang and Geddes 1997) or the 
necrotic type of cell death associated with glutamate 
(Schinder et al., 1996, Dubinsky and Levi 1998, Brustovetsky 
and Dubinsky 2000). This suggested mechanism could 
be supported through considering the recent work of 
Genius et al. (2012) who reported that creatine effectively 
antagonized the hydrogen peroxide (H2O2)-induced ATP 
depletion and the excitotoxic response towards gluta-
mate, while not directly acting as an antioxidant.  
Transgenic rat and mouse models have now proved to 
be one of the most useful tools to understand the com-






Figure 4. Histogram showing the percentage of DNA damage incurred by the treatment of neuroblastoma cells SH-SY5Y with and without 
different concentrations of propionic acid (PA) (5 and 10 mM), in presence and absence of creatine (CR) at different doses (12 and 24 mM) 
for 24 and 48 h. The percentage of DNA damage was automatically calculated by the DNA tail length and the distribution of the DNA in the 





plexity of neurodegenerative disease, such as Huntington’s 
disease, Parkinson’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis (ALS). They are also ex-
tremely useful in evaluating new therapeutics. Several 
years ago, Ferrante et al. (2000) and Zhang et al. (2003) 
administered creatine orally at various doses (1 and 2% 
of diet) to the mouse model of Huntington’s and ALS. 
Interestingly, they found that creatine chronically adminis-
tered before clinical disease onset could substantially 
delay onset of disease and prolong survival of the mice. It 
also delayed degeneration of motor neurons. For this 
reason, groups around the world soon began trials of 
using creatine in ALS. Although, the mouse trials sug-
gested the effectiveness of creatine, unfortunately, human 
trials using creatine were unsuccessful (Rothstein, 2003). 
The most obvious answer for this failed human trial is that 
all preclinical models inherently have certain limitations. 
The culture models typically reflected immature, embryo-
nic, or young postnatal motor neurons that are essentially 
on a short path to death (cultured motor neurons only 
survive a few weeks in vitro), and, also they are devoid of 
their neighbours as astrocytes, oligodendroglia, or micro-
glia. This could help to suggest that in most of neuro-
degenerative diseases neurons do not die alone (Gong et 
al., 2000; Lino et al., 2002, Raoul et al., 2002). It appears 
that surrounding neurophil (microglia, astrocytes and 
possible other cells) all contribute to and are essential for 
the death of motor neurons. Even the neurodegenerative 
transgenic rodents have limitations. 
First  and  the most important consideration when plan- 
ning human trials is the dose equivalent. Therefore, failure 
of human trials using creatine does not oppose its neuro-
protective effects but there are several variables that one 
has to consider when making these human trials. Among 
this is the use of different drug concentrations and at 
different times of drug delivery (before clinical disease 
onset, at disease onset, and after disease begins in the 
mice). Ideally, all of these variables should be evaluated 
before starting a human trial, but they are not all practical 
and economically feasible. 
With the limited researches, important unsolved ques-
tions regarding the dose and mechanism of action for 
creatine neuroprotection remains. However, it is still 
promising as a neuroprotective agent for further studies 
in the future, involving neurological and psychological dis-
eases. More follow-up studies and trials on a larger scale 
are necessary in order to establish the optimum dose, 
and assess its effects on human subjects (Andres et al., 
2008). Based on the present study together with selected 
previous in vivo studies, the protective effect of creatine 
seems to be related to its potency in maintaining mito-
chondrial bioenergetics. Increase of mitochondrial mem-
brane potential, decrease of intra-mitochondrial levels of 
reactive oxygen species and calcium, together with the 
maintenance of adenosine triphosphate (ATP), ATP/ADP 
and PCr/Cr levels were reported as mechanistic aspects 
of  the protective effect of creatine (Klivenyi et al., 2004; 
Sullivan et al., 2000; El-Ansary et al., 2011a). 
Most of the general therapies as vitamin C, vitamin E, 
glutathione, Coenzyme Q, creatine and idebenone are






Figure 5. Images of the 1.2% agarose gel of genomic DNA extracted, following 
exposure of neuroblastoma cell SH-SY5Y for (A) 24 h and (B) 48 h with and without 
propionate (P) in the presence and absence of creatine (CR). Lane 1, DNA isolated 
from control cells; Lanes 2 and 3, SH-SY5Y cells treated with 5 and 10 mM of P, 
respectively. Lanes 4 and 5, Cells treated with 12 and 24 mM of CR alone. Lanes 6 
and 7, Cells pretreated with 12 and 24 mM CR before 10 mM P treatment. Lanes 8 
and 9 are cells that were pretreated with 12 and 24 mM CR before 5 mM P 
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Figure 6. Histogram showing the number of fragmented DNA bands obtained for the control and treated 
neuroblastoma cells SH-SY5Y. Neuroblastoma cells SH5Y were treated for 24 and 48 h without and with 5 and 10 
mM PA in the presence and absence of creatine (CR) doses (12 and 24 mM). The genomic DNA were isolated from 
the above cells and run on 1.5% agaros gel electrophoresis, followed by staining with ethidium bromide and 
photographed under UV light.  The number of fragmented bands was calculated by scanning the fluorescent DNA 






Figure 7. Histograms showing percentage of compact DNA within 24 and 48 h after propionic acid (PA) treatments (5 and 
10 mM) in the presence and absence of creatine (CR) pretreatments (12 and 24 mM). The photograph containing 
fluorescent distribution of DNA on the gel was scanned by a digitizing densitometer as described by Freeman & 




harmless at their usual doses, although some may be 
expensive. In the absence of any other proven therapy in 
mitochondrial disease, many clinicians resort, on theore-
tical or anecdotal grounds alone, to ‘mitochondrial cock-
tails’ of various combinations of these agents to treat their 
patients (Klopstockv et al., 2011). 
Conclusions 
 
In line with several previous studies, our results empha-
size the neurotoxicity of PA, which was clearly seen 
through the increased DNA fragmentation in both comet 
assay  and  DNA  ladder, indicating apoptotic activities in  




neuroblastoma that occurred in a time- and dose-depen-
dent manner.  
Our results confirm a possible protective effect for 
creatine on neuroblastoma, as it appears to attenuate 
PA- induced toxicity, as revealed by the decrease in DNA 
fragmentation in the cells pretreated with creatine, shown 
in both comet assay and DNA laddering.  Creatine seems 
to be very promising as a neuroprotective agent. More 
experiments follow-up studies and clinical trials are 
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